SCHEMBL29615433

SCHEMBL29615433

CCO/C=C/c1cc(OCc2ccc(-c3cnn(C)c3)cc2)ncn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 1/20 0.38
▸ KIT P10721 3/20 0.35
▸ ACVR1 Q04771 1/20 0.35
▸ LRRK2 Q5S007 2/20 0.35
▸ PLA2G7 Q13093 1/20 0.35
▸ CCNC P24863 2/20 0.34
▸ CDK8 P49336 2/20 0.34
▸ NTRK1 P04629 1/20 0.34
▸ CSF1R P07333 1/20 0.34
▸ NTRK3 Q16288 1/20 0.34
▸ NTRK2 Q16620 1/20 0.34
▸ KDR P35968 2/20 0.34
▸ EPHB4 P54760 2/20 0.34
▸ TEK Q02763 2/20 0.34
▸ CYP11B1 P15538 1/20 0.34
▸ CYP11B2 P19099 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34
▸ CCNK O75909 1/20 0.34
▸ CDK12 Q9NYV4 1/20 0.34
▸ AXL P30530 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28862431 1.00 PRMT5 (0.38) PRMT5KITACVR1LRRK2PLA2G7
SCHEMBL29614180 0.82 KIT (0.51) KITLRRK2CSF1R
SCHEMBL22918645 0.82 KIT (0.51) KITLRRK2CSF1R
SCHEMBL29709020 0.82 KIT (0.51) KITLRRK2CSF1R
SCHEMBL29615266 0.76 GPR55 (0.48) KIT
SCHEMBL28862468 0.76 GPR55 (0.48) KIT
SCHEMBL34464686 0.73 CCNC (0.44) PRMT5LRRK2CCNCCDK8NTRK1
SCHEMBL28862448 0.72 MKNK1 (0.41) KITCCNCCDK8CSF1R
SCHEMBL29615564 0.72 MKNK1 (0.41) KITCCNCCDK8CSF1R
SCHEMBL12936662 0.67 EPHB4 (0.48) ACVR1CCNCCDK8NTRK1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109697-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2026-04-23 — — US disclosed
CN-118955500-A 4- (Imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives 默克专利股份公司 2024-11-15 — — CN disclosed
US-20220267320-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2022-08-25 — — US disclosed
EP-4003992-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL) -PYRIMIDINE DERIVATIVES Merck Patent GmbH (DE) 2022-06-01 — — EP disclosed
CN-114174293-A 4- (imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives 默克专利股份公司 2022-03-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109697-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES CHUK, CNKSR1, KIT PRMT5 2789/4885KIT 3/4885ACVR1 942/4885
US-20220267320-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES NCOA3, NCOR1, NCOA4 PRMT5 2195/4885KIT 273/4885ACVR1 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback